The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Biorepository
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas A. Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Kanwal Zeeshan 847.570.1697
Open to Enrollment: Yes
E4512: Testing the Addition of Drug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition of crizotinib may help prevent your cancer from returning, but it could also cause side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas A. Hensing, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes
A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to determine if patietns iwth Non-Small Cell Lung Cancer (NSCLC) have a mutation (abnormal change) in the DNA or their tumor and if so, which one. The genetic mutations which are being assessed are: EGFR, ALK, an dPD-L1. Not all lung tumors have the changes in genes. The study will lead into two optional treatment trials which will use specific drugs to target these genes as well as tumors without mutations. Tissue from the tumor removed at the time of surgery is sent to a national laboratory to be analyzed and compared to local results.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stage IB, II, IIIA
Principal Investigator: Thomas A. Hensing, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes
A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this research study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (and investigational drug).
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Thomas A. Hensing, MD
IRB Approval Number: EH15-123
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes
Best Practive in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study which will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo Surgery
Contact: Interested participants may contact Ujala Bokhary, MBBS, CCRP at 847.570.1783 ubokhary@northshore.org
Open to Enrollment: Yes
EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Aims: The purpose of this research study is to find out whether treatment with nivolumab (also known as OPDIVO), a type of immunotherapy will result in improved survival over placebo for patients with STage IB-IIIA NSCLC following complete resection and standard post-operative therapy. This study is the treatment trial linked to A151216 Alchemist trial withere the tissue is sent for determiniation of gene mutations post operatively.
Diagnosis: Non-Small Cell Lung Cancer (NSCLC) Stages IB, II, IIIA
Principal Investigator: Thomas A. Hensing, MD
IRB Approval Number: EH16-268
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes